Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), teer decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
we decrease » _ decrease (Expand Search), teer decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
10121
Supplementary Material for: Association of platelet count and mean platelet volume with fish intake frequency: Implication for the cardioprotective effect of fish intake
Published 2025“…Introduction: Mean platelet volume (MPV) measures platelet activity, and high values indicate increased atherosclerotic cardiovascular disease (ASCVD) risk. …”
-
10122
CsrA modulates the expression of a thiamine pyrophosphate (TPP) riboswitch element.
Published 2017“…<b>B</b>) EMSA with 200nM of biotinylated thi-element (TPP) RNA and purified CsrA: Lane 1: no CsrA, lane 2: 1.0 μM CsrA, lane 3: 2.0 μM CsrA, lane 4: 5.0 μM CsrA, lane 5: 5.0 μM CsrA + 2.0 μM unlabeled RsmZ. …”
-
10123
Depletion of xlPTP4A3 inhibits both migration of NCC and uveal melanoma cells.
Published 2013“…B) Timelapse videomicroscopy of stage 17-derived NCC treated with a pharmacological inhibitor of PTP4A3, a rhodanine derivative (PRL-3 inhibitor I), shows that inhibition of PTP4A3 increases the average of pausing NC cells and strongly decreases the migration velocity of the treated cells (relative to that of vehicle treated cells). …”
-
10124
-
10125
De-identified dataset.
Published 2024“…</p><p>Results</p><p>The median age of the 37 participants at enrollment was 70.5 years; 30 (81%) had prior SARS-CoV-2 infection, and 76% received Pfizer-BioNTech and 24% Moderna homologous vaccines. …”
-
10126
Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4<sup>+</sup>CD45RB<sup>high</...
Published 2019“…MT-1303 phosphate (MT-1303-P), an active metabolite of MT-1303, exhibits S1P<sub>1</sub> receptor agonism at a lower EC<sub>50</sub> value than other S1P<sub>1</sub> receptor modulators currently being developed. …”
-
10127
ND5 mutant mitochondria have a reduced ability to buffer calcium.
Published 2016“…Control (CON) cybrid mitochondria were able to buffer more calcium than both ND5 mutant cybrid mitochondria and ρ<sup>0</sup> cell mitochondria. …”
-
10128
Root phenotype of <i>ibr5</i> alleles compared to wild-type.
Published 2015“…L<i>er</i> roots show a 55<b>%</b> decrease in root length when grown on 10 mM IAA compared to un-supplemented medium and <i>tink/ibr5-6</i> plants show a similar root inhibition phenotype (p value ≤ 0.3). …”
-
10129
DN Rab5 (S34N) retards endocytosis of KCa2.3.
Published 2013“…</b> Expression of S34N Rab5 resulted in a significant decrease of KCa2.3 endocytosis, relative to WT Rab5 (<i>n</i> = 3; *P<0.05). …”
-
10130
Image_1_Eph-ephrin Signaling Affects Eye Lens Fiber Cell Intracellular Voltage and Membrane Conductance.TIF
Published 2021“…Immunostaining revealed changes in connexin 50 (Cx50) subcellular localization in EphA2<sup>–/–</sup> peripheral lens fibers and alteration in aquaporin 0 (Aqp0) staining patterns in ephrin-A5<sup>–/–</sup> and EphA2<sup>–/–</sup> inner mature fiber cells. …”
-
10131
-
10132
-
10133
-
10134
Subgroup analysis.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
10135
Study outcomes.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
10136
Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV.
Published 2021“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal MERS-CoV infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 43% survival in a lethal MERS-CoV infection (B) and produced a statistically significant decrease in lung viral titer at the highest dose tested (C). …”
-
10137
Intranasal NIC-hLYS is efficacious in vivo against MERS-CoV.
Published 2021“…<p>The efficacy of NIC-hLYS particles was assessed in a lethal SARS-CoV-2 infection model (A). Once daily intranasal administration of NIC-hLYS particles suspended in 0.45% sodium chloride resulted in 30% survival in a lethal SARS-CoV-2 infection (B) and produced a statistically significant decrease in lung viral titers after 10 days of dosing (C). …”
-
10138
Histological abnormalities in E18.5 ATF2 mutant cerebellum and brainstem.
Published 2011“…Number of hypoglossal motoneurons (h) is bilaterally decreased in <i>Atf2<sup>−/−</sup></i> embryos while number of dorsal vagal motoneurons (v) appears normal. …”
-
10139
Adverse events <sup>a</sup>.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
-
10140
Rhinorrhea-free days up to day 10.
Published 2024“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”